. 2019 Jan 5;9(4):794–808. doi: 10.1016/j.apsb.2019.01.001
© 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1.
TCP-based LSD1 inhibitors.